GlassScriptPhysician profile
Carla Jude Simon
NPI 1912974551
$4,963.10
in general payments reported to CMS, 2019-2025
26 companies · $591 in 2025
The $591 reported for 2025 was more than what 91% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $874 · 2020: $588 · 2021: $166 · 2022: $680 · 2023: $841 · 2024: $1,224 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,655.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $635.91 | 2021-2025 | Teflaro |
| Janssen Pharmaceuticals, INC | $628.18 | 2019-2024 | Xarelto |
| Gilead Sciences, INC. | $530.91 | 2022-2025 | Veklury |
| Boehringer Ingelheim Pharmaceuticals, INC. | $456.96 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Novartis Pharmaceuticals Corporation | $401.47 | 2019-2024 | |
| Pfizer INC. | $239.40 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $209.41 | 2019 | |
| Alnylam Pharmaceuticals INC. | $205.22 | 2022-2025 | Givlaari |
| Allergan, INC. | $198.63 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $181.89 | 2019-2024 | Nuzyra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $148.51 | 2019-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $148.41 | 2019-2024 | Fasenra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $147.49 | 2025 | |
| Boston Scientific Corporation | $132.95 | 2019-2025 | Watchman Flx, Watchman Access System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $128.55 | 2020-2025 | Lifevest |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $118.34 | 2019-2024 | Verquvo, Dificid, Zerbaxa |
| Melinta Therapeutics, LLC | $104.96 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $74.85 | 2019 | |
| Electromed, INC. | $66.18 | 2021-2024 | Smartvest |
| Alexion Pharmaceuticals, INC. | $51.20 | 2019-2022 | |
| Inari Medical, INC. | $36.92 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Scpharmaceuticals INC. | $35.32 | 2024 | |
| Abbott Laboratories | $23.78 | 2024 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $21.65 | 2020 | |
| Glaxosmithkline, LLC. | $20.02 | 2025 | Trelegy Ellipta |
| Shire North American Group INC | $15.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carla Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.